RT Journal Article
SR Electronic
T1 Glucose response to low-dose glucagon for insulin-induced mild hypoglycaemia after 12 weeks of high versus low carbohydrate diet. A pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.30.20222794
DO 10.1101/2020.10.30.20222794
A1 Ranjan, Ajenthen G.
A1 Schmidt, Signe
A1 Holst, Jens J.
A1 Christensen, Merete B.
A1 Nørgaard, Kirsten
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.30.20222794.abstract
AB Objective To compare the glucose response to low-dose glucagon after high carbohydrate diet (HCD) versus low carbohydrate diet (LCD).Methods Individuals with insulin pump-treated type 1 diabetes went through 12 weeks of HCD (>250 g/day) and 12 weeks of LCD (<100 g/day) in random order and separated by 12 weeks. At end of each diet, mild hypoglycaemia was induced in the fasting state by a subcutaneous insulin bolus. When plasma glucose (PG) reached 3.9 mmol/L, 100 µg glucagon was given subcutaneously.Results Four of six participants completed both study visits while the remaining two only completed the study visit following LCD. They were 37 (28-52) years old (median (IQR)), had BMI 25.0 (24.5-25.2) kg/m2, and HbA1c 57 (55-59) mmol/mol or 7.4 (7.2-7.5) %. Daily carbohydrate intake was 95 (86-97) g during LCD and 254 (184-259) g during HCD. Compared with HCD, LCD had a significantly lower area under the PG curve from 0-120 min (521 (394-617) vs 663 (546-746) mmol/l x min, p=0.045) and insignificant lower incremental PG peak after the glucagon bolus (1.5 (0.6-3.2) vs 3.0 (2.2-4.2) mmol/L, p=0.317).Conclusion In conclusion, the glucose response to low-dose glucagon was reduced after 12 weeks of LCD compared with HCD.Competing Interest StatementA.R. and M.B.C have nothing to disclose. S.S. has served on advisory boards for Roche Diabetes Care and Medtronic. K.N. serves as adviser to Medtronic, Abbott, Sanofi and Novo Nordisk, owns shares in Novo Nordisk, has received research grants from Novo Nordisk, Roche Diabetes Care and Zealand Pharma, and has received fees for speaking from Medtronic, Roche Diabetes Care, Rubin Medical, Sanofi, Novo Nordisk A/S, Zealand Pharma and Bayer. J.J.H. has served on advisory boards for Novo Nordisk.Clinical TrialNCT02888691Funding StatementThis work was funded by a research grant from the Danish Diabetes Association and the Danish Diabetes Academy supported by the Novo Nordisk Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Regional Committee on Health Research Ethics (H-1509662) and the Danish Data Protection Agency approved the study, which was conducted in accordance with the Helsinki Declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets and the full trial protocol can be requested from the corresponding author.